Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: A real- world 24-week study

Abstract

Abstract Background Roxadustat is an oral hypoxy inducing factor-prolyl hydroxylase inhibitor (HIF-PHI) that regulates iron metabolism in patients with chronic kidney disease (CKD) primarily by reducing hepcidin levels and mobilizing internal iron stores. More data are needed to demonstrate the efficacy of roxadustat in regulating iron metabolism in patients with peritoneal dialysis (PD) compared with erythropoiesis stimulating agents (ESAs). Methods This prospective cohort study enrolled PD patients with a mean hemoglobin level of 60 to 100 g/L. All subjects were randomized into two groups at a ratio of 2:1: the roxadustat group (106 cases), and the ESA group (53 cases). The primary endpoint was the change in the iron biomarker levels and the proportion of patients with absolute iron deficiency and functional iron deficiency. Results Compared with ESAs, roxadustat significantly decreased hepcidin level (difference,-20.09ng/mL; 95% CI, -30.26 to -9.92), attenuated the increase in serum soluble transferrin receptor (sTFR) level (difference, -7.87 nmol/L; 95% CI, -12.11 to -3.64), and reduced the proportion of patients with functional iron deficiency (roxadustat, 11.43%; ESA, 33.33%). There was no significant difference in safety of the two groups over the duration of the study. Conclusions Compared with ESA group, roxadustat group showed significant difffferences in all iron biomarker levels except serum ferritin (sFt) and transferrin saturation (TSAT). These results suggest that roxadustat was superior to ESAs as a therapy for iron metabolism in PD patients. Trial registration: This study completed Chinese Clinical Trial Registration on March 4,2022 (registration number: ChiCTR2200057231).